John Engel

John is the lead equity analyst for Stansberry Innovations Report, a monthly research advisory that shows subscribers how to invest safely in the next technology revolutions. He and the Innovations team look for strong companies that are staking out their spots in the burgeoning technology industry, treating shareholders right, and providing the opportunity for outstanding gains.

John holds a Master of Science from Johns Hopkins University and has real world experience working at both a biotech startup and large pharmaceutical company. Prior to joining Stansberry Research, John worked as a research scientist in a drug discovery lab where he spent years developing novel therapeutics.

He is also a research analyst for Stansberry Venture Technology – our premium advisory service focused on emerging technologies and biotechnologies. And he is a contributor to our flagship publication Stansberry’s Investment Advisory.

John is a valuable asset to our team as we hunt for and analyze new scientific breakthroughs.